Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate~* Patient must be ineligible for traditional myeloablative transplantation according to treating physician~* Lack of 6/6 or 5/6 HLA-matched related, 8/8 HLA-matched unrelated donor, or unrelated donor not available within a time frame necessary to perform a potentially curative stem cell transplant~* 18-65 years of age~* ECOG Performance Status 0-2~Exclusion Criteria:~* The following hematologic malignancies are excluded:~  * Myelofibrosis unless there has been exposure to cytotoxic chemotherapy for the treatment of progression to acute myeloid leukemia~ * Chronic Myelogenous Leukemia, unless there has been exposure to cytotoxic chemotherapy for the treatment of blast phase, 3) Aplastic anemia, in the absence of transformation to Myelodysplastic disorder~* Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular dysfunction as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension~* Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of \< 50% of predicted, corrected hemoglobin~* Renal disease: serum creatinine \> 2.0mg/dl~* Hepatic disease: serum bilirubin \> 2.0mg/dl (expect in the case of Gilbert's syndrome or ongoing hemolytic anemia), SGOT or SGPT \> 3 x upper limit of normal~* Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation~* HIV antibody~* Uncontrolled infection~* Pregnancy or breast feeding mother~* Inability to comply with the requirements for care after allogeneic stem cell transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): 2 umbilical cord units: Second cord blood unit modulated with ProHema
- Group 2 (Type: ACTIVE_COMPARATOR): 2 umbilical cord units: First cord blood unit modulated with ProHema

Based on this trial design, predict the completion outcome and termination type (if applicable).